Search results
Moderna, Merck say vaccine improved survival in patients with deadly skin cancer
CNBC· 10 hours agoModerna and Merck released more positive three-year data Monday on their experimental vaccine, given...
Moderna-Merck skin cancer vaccine shows survival benefit in long-term follow-up
Reuters· 10 hours ago, opens new tab said on Monday their cancer vaccine in combination with blockbuster cancer therapy...
Experimental mRNA vaccines gain steam with promising cancer trial results
Semafor via Yahoo News· 3 hours agoMelanoma patients who received monthly mRNA vaccines and Merck’s Keytruda immunotherapy had lower...
Moderna, Merck shares rise as combined melanoma therapy shows improved survival rate By...
Investing.com· 8 hours agoModerna (NASDAQ:MRNA) and Merck (MRK) have released new, more encouraging three-year data on their...
Promising trial data for Moderna's skin cancer vaccine sends stock rising
Quartz· 4 hours agoModerna stock jumped nearly 4% on Tuesday after the the company announced positive data from an...
An mRNA Melanoma Vaccine Shows Promise
Time Magazine· 11 hours agoModerna says the same mRNA technology that fueled its COVID-19 vaccine is proving effective in fighting melanoma. The company presented the latest...
Merck eyes purchase of ophthalmology company
WFMZ Eastern Pennsylvania and Western New Jersey· 5 days agoTake Merck, for example. Its blockbuster cancer drug, Keytruda, is now the largest selling drug in the world. In the past few weeks, studies have shown...
Merck Reaches $1.3 Billion Deal for Eye-Drug Company EyeBio
The Wall Street Journal· 5 days agoMerck, of Rahway, N.J., had sold some ophthalmology drugs, but it abandoned the market about a...
Merck to Acquire EyeBio
Morningstar· 6 days ago“We continue to execute on our science-led business development strategy to expand and diversify our pipeline,” said Dr. Dean Y. Li, president...
Is Moderna Stock A Buy As The U.S. Government Mulls Its Bird Flu Vaccine?
Investor's Business Daily· 3 days agoNotably, Moderna kept its outlook for the year. Meanwhile, Moderna is expanding its efforts in...
